Brokers Issue Forecasts for Check-Cap FY2026 Earnings

Check-Cap Ltd (NASDAQ:MBAI) – Stock analysts at Northland Securities issued their FY2026 earnings per share estimates for shares of Check-Cap in a research note issued to investors on Monday, September 28th. Northland Securities analyst M. Latimore forecasts that the company will post earnings per share of ($0.02) for the year. Northland Securities has a “Outperform” rating and a $10.00 price objective on the stock. Northland Securities also issued estimates for Check-Cap’s FY2027 earnings at $0.00 EPS, FY2028 earnings at $0.19 EPS and FY2029 earnings at $0.58 EPS.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Check-Cap in a research report on Tuesday, July 21st. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $10.00.

Check-Cap Stock Performance

NASDAQ:MBAI opened at $3.75 on Wednesday. The stock has a fifty day moving average price of $7.11 and a 200-day moving average price of $9.43. The company has a market cap of $5.16 million, a price-to-earnings ratio of -0.27 and a beta of 0.67. Check-Cap has a fifty-two week low of $3.75 and a fifty-two week high of $27.44.

Check-Cap Company Profile

Check-Cap Ltd. was an Israel-based medical diagnostics company focused on developing noninvasive technologies for colorectal cancer screening. Its lead product, C-Scan, was an ingestible, capsule-based imaging system designed to examine the colon for polyps and other abnormalities without requiring the extensive bowel preparation typically associated with conventional colonoscopy.

The C-Scan system was intended to combine a disposable capsule with an external tracking and data-collection system, allowing physicians to review images of the gastrointestinal tract after the capsule passed through the body.